Combination Therapy for Schizophrenia Cognitive Symptoms and GI Tolerance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antipsychotic drugs are ineffective in managing the negative and cognitive symptoms of schizophrenia, leading to poor social and functional outcomes, and there is a lack of novel therapeutic approaches for addressing these symptoms.
Innovation Solution
A combination therapy comprising an alpha-7 nicotinic acetylcholine receptor agonist with 5-HT3 receptor inhibitory activity and a serotonin agonist is administered to mitigate gastrointestinal side effects and effectively ameliorate positive, negative, and cognitive symptoms of schizophrenia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dopaminergic-based antipsychotic drugs are used to manage positive symptoms, then positive symptoms are improved, but negative and cognitive symptoms remain unaffected
Solution Approach 1:
The patent combines multiple mechanisms of action into a single therapeutic approach: the compound simultaneously antagonizes D2 dopamine receptors (for positive symptoms), activates alpha-7 nicotinic acetylcholine receptors (for cognitive symptoms), and modulates 5-HT3 serotonin receptors (for negative symptoms and gastrointestinal side effects). This multi-target combination resolves the contradiction by making one treatment effective across all symptom types rather than requiring separate medications for different symptom clusters.
Solution Approach 2:
The therapeutic compound is designed with multi-functional properties to address diverse symptom domains through a single agent. It universally acts on multiple receptor systems (dopamine, acetylcholine, serotonin) to simultaneously manage positive, negative, and cognitive symptoms, eliminating the need for multiple specialized medications and improving overall treatment versatility.
2Reliability
If alpha-7 nicotinic acetylcholine receptor agonists are used to improve cognitive symptoms, then cognitive symptoms are improved, but gastrointestinal side effects occur
Solution Approach 1:
The patent introduces 5-HT3 receptor modulation as an intermediary mechanism that mediates between the cognitive benefits of alpha-7 activation and the gastrointestinal side effects. By simultaneously activating alpha-7 receptors for cognitive improvement while modulating 5-HT3 receptors to counteract gastrointestinal effects, the compound uses multiple pathways to resolve the contradiction between therapeutic benefit and harmful side effects.
Solution Approach 2:
The patent changes the pharmacological parameters by using a compound with dual activity profiles: strong alpha-7 agonist activity for cognitive benefits and 5-HT3 modulatory activity to control gastrointestinal effects. This parameter change allows the same compound to produce both desired therapeutic effects and reduced side effects by adjusting the balance of receptor activations.
3Duration of action of stationary object
If current antipsychotic medications are used for chronic treatment, then positive symptoms are managed, but quality of life remains poor due to lack of effect on negative and cognitive symptoms
Solution Approach 1:
The patent merges multiple therapeutic mechanisms into a single chronic treatment regimen that simultaneously addresses positive, negative, and cognitive symptoms. This combination allows for sustained long-term treatment that improves overall quality of life rather than merely maintaining control of positive symptoms, as the multi-target approach continuously benefits all symptom domains throughout chronic therapy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination therapy successfully reduces negative and cognitive symptoms of schizophrenia while minimizing gastrointestinal side effects, facilitating long-term treatment and improving quality of life.
Implementation Method 1
an alpha-7 nicotinic acetylcholine receptor agonist having 5-HT3 receptor inhibitory activity
Implementation Method 2
an alpha-7 nicotinic acetylcholine receptor agonist having 5-HT3 receptor inhibitory activity
Implementation Method 3
a serotonin agonist useful in the effective treatment of a schizophrenic disorder
Data Source
AI summary
The present specification disclose a combined therapy comprising one or more activators of an alpha-7 nicotinic acetylcholine receptor activity having 5-HT3 receptor inhibitory activity and one or more activators of 5-HT3 receptor activity for use in treating a schizophrenic disorder as well as methods of treating a schizophrenic disorder by administering a combined therapy comprising one or more activators of an alpha-7 nicotinic acetylcholine receptor activity having 5-HT3 receptor inhibitory activity and one or more activators of 5-HT3 receptor activity.